MSH6 is an inclusion criterion in 77 clinical trials for malignant solid tumor, of which 67 are open and 10 are closed. Of the trials that contain MSH6 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 41 are phase 1 (34 open), 10 are phase 1/phase 2 (8 open), and 25 are phase 2 (24 open) [4].

Pembrolizumab has evidence of efficacy in patients with MSH6 mutation in malignant solid tumor [4].

MSH6 is an inclusion criterion in 53 clinical trials for colorectal carcinoma, of which 41 are open and 12 are closed. Of the trials that contain MSH6 status and colorectal carcinoma as inclusion criteria, 27 are phase 1 (21 open), 8 are phase 1/phase 2 (5 open), 15 are phase 2 (12 open), and 3 are phase 3 (3 open) [4].

Ipilimumab, nivolumab, and pembrolizumab have evidence of efficacy in patients with MSH6 mutation in colorectal carcinoma [4].

MSH6 is an inclusion criterion in 25 clinical trials for endometrial carcinoma, of which 22 are open and 3 are closed. Of the trials that contain MSH6 status and endometrial carcinoma as inclusion criteria, 14 are phase 1 (12 open), 4 are phase 1/phase 2 (3 open), and 7 are phase 2 (7 open) [4].

Dostarlimab has evidence of efficacy in patients with MSH6 mutation in endometrial carcinoma [4].

MSH6 is an inclusion criterion in 2 clinical trials for endometrial adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

Nivolumab has evidence of efficacy in patients with MSH6 mutation in endometrial adenocarcinoma [4].

MSH6 is an inclusion criterion in 46 clinical trials for non-small cell lung carcinoma, of which 37 are open and 9 are closed. Of the trials that contain MSH6 status and non-small cell lung carcinoma as inclusion criteria, 29 are phase 1 (22 open), 9 are phase 1/phase 2 (7 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 40 clinical trials for melanoma, of which 32 are open and 8 are closed. Of the trials that contain MSH6 status and melanoma as inclusion criteria, 27 are phase 1 (20 open), 7 are phase 1/phase 2 (6 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 36 clinical trials for head and neck squamous cell carcinoma, of which 28 are open and 8 are closed. Of the trials that contain MSH6 status and head and neck squamous cell carcinoma as inclusion criteria, 24 are phase 1 (18 open), 7 are phase 1/phase 2 (5 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 32 clinical trials for breast carcinoma, of which 24 are open and 8 are closed. Of the trials that contain MSH6 status and breast carcinoma as inclusion criteria, 21 are phase 1 (15 open), 4 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 32 clinical trials for urothelial carcinoma, of which 25 are open and 7 are closed. Of the trials that contain MSH6 status and urothelial carcinoma as inclusion criteria, 20 are phase 1 (14 open), 6 are phase 1/phase 2 (5 open), and 6 are phase 2 (6 open) [4].

MSH6 is an inclusion criterion in 30 clinical trials for renal cell carcinoma, of which 24 are open and 6 are closed. Of the trials that contain MSH6 status and renal cell carcinoma as inclusion criteria, 15 are phase 1 (11 open), 9 are phase 1/phase 2 (7 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 28 clinical trials for gastric carcinoma, of which 23 are open and 5 are closed. Of the trials that contain MSH6 status and gastric carcinoma as inclusion criteria, 17 are phase 1 (13 open), 5 are phase 1/phase 2 (5 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 25 clinical trials for cervical carcinoma, of which 21 are open and 4 are closed. Of the trials that contain MSH6 status and cervical carcinoma as inclusion criteria, 16 are phase 1 (13 open), 5 are phase 1/phase 2 (4 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 22 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 19 are open and 3 are closed. Of the trials that contain MSH6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 11 are phase 1 (9 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 22 clinical trials for hepatocellular carcinoma, of which 19 are open and 3 are closed. Of the trials that contain MSH6 status and hepatocellular carcinoma as inclusion criteria, 12 are phase 1 (9 open), 5 are phase 1/phase 2 (5 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 21 clinical trials for small cell lung carcinoma, of which 19 are open and 2 are closed. Of the trials that contain MSH6 status and small cell lung carcinoma as inclusion criteria, 12 are phase 1 (10 open), 5 are phase 1/phase 2 (5 open), and 4 are phase 2 (4 open) [4].

MSH6 is an inclusion criterion in 20 clinical trials for ovarian carcinoma, of which 14 are open and 6 are closed. Of the trials that contain MSH6 status and ovarian carcinoma as inclusion criteria, 14 are phase 1 (10 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 16 clinical trials for Merkel cell carcinoma, of which 13 are open and 3 are closed. Of the trials that contain MSH6 status and Merkel cell carcinoma as inclusion criteria, 10 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 15 clinical trials for prostate adenocarcinoma, of which 14 are open and 1 is closed. Of the trials that contain MSH6 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 11 are phase 2 (10 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 14 clinical trials for bladder carcinoma, of which 11 are open and 3 are closed. Of the trials that contain MSH6 status and bladder carcinoma as inclusion criteria, 8 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 14 clinical trials for gastric adenocarcinoma, of which 12 are open and 2 are closed. Of the trials that contain MSH6 status and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (6 open) and 7 are phase 2 (6 open) [4].

MSH6 is an inclusion criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain MSH6 status and prostate carcinoma as inclusion criteria, 7 are phase 1 (6 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (4 open) [4].

MSH6 is an inclusion criterion in 11 clinical trials for esophageal carcinoma, of which 9 are open and 2 are closed. Of the trials that contain MSH6 status and esophageal carcinoma as inclusion criteria, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (4 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 11 clinical trials for mesothelioma, of which 9 are open and 2 are closed. Of the trials that contain MSH6 status and mesothelioma as inclusion criteria, 9 are phase 1 (7 open) and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 11 clinical trials for pancreatic carcinoma, of which 9 are open and 2 are closed. Of the trials that contain MSH6 status and pancreatic carcinoma as inclusion criteria, 6 are phase 1 (4 open) and 5 are phase 2 (5 open) [4].

MSH6 is an inclusion criterion in 9 clinical trials for skin squamous cell carcinoma, of which 8 are open and 1 is closed. Of the trials that contain MSH6 status and skin squamous cell carcinoma as inclusion criteria, 8 are phase 1 (7 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 8 clinical trials for colorectal adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain MSH6 status and colorectal adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 8 clinical trials for head and neck carcinoma, of which 6 are open and 2 are closed. Of the trials that contain MSH6 status and head and neck carcinoma as inclusion criteria, 6 are phase 1 (4 open) and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 6 clinical trials for fallopian tube carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH6 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 6 clinical trials for primary peritoneal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH6 status and primary peritoneal carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 5 clinical trials for anal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MSH6 status and anal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 5 clinical trials for cholangiocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain MSH6 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 5 clinical trials for classical hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain MSH6 status and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 5 clinical trials for esophageal squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain MSH6 status and esophageal squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 4 clinical trials for basal cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MSH6 status and basal cell carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 2 are open and 2 are closed. Of the trials that contain MSH6 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for biliary tract carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for colon adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and colon adenocarcinoma as inclusion criteria, 3 are phase 3 (3 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and colon carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for cutaneous melanoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and endometrial serous adenocarcinoma as inclusion criteria, 3 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for esophagogastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and esophagogastric carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for malignant uterine neoplasm, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for nasopharyngeal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and nasopharyngeal carcinoma as inclusion criteria, 3 are phase 1 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and pancreatic ductal adenocarcinoma as inclusion criteria, 3 are phase 1 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for rectal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and rectal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for salivary gland carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and salivary gland carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for thyroid gland carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and thyroid gland carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 3 clinical trials for vulvar carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and vulvar carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for adnexal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and adnexal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for anal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for cancer, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and cancer as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for endometrial clear cell adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and endometrial clear cell adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for endometrial undifferentiated carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and endometrial undifferentiated carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for gallbladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and gallbladder carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for glioma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and glioma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and lymphoma as inclusion criteria, 2 are phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for malignant ovarian epithelial tumor, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and neuroendocrine carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for non-clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for squamous cell carcinoma of the penis, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for thymic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and thymic carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

MSH6 is an inclusion criterion in 2 clinical trials for vaginal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and acral lentiginous melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for appendix carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and appendix carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for appendix neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and appendix neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for bone sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bone sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and carcinoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for colon neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and colon neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for endometrial mixed adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for gallbladder adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and gallbladder adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for high-grade endometrial stromal sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and high-grade endometrial stromal sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for lynch syndrome, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and lynch syndrome as inclusion criteria, 1 is phase 3 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for malignant uterine corpus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant uterine corpus neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ocular melanoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ocular melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian clear cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinofibroma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian endometrioid adenocarcinofibroma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and pancreatic neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for rectal neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and rectal neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for skin carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and skin carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and small intestinal adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for small intestinal neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and small intestinal neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for thymoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and thymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for undifferentiated (embryonal) sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and undifferentiated (embryonal) sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH6 is an inclusion criterion in 1 clinical trial for vulvar squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and vulvar squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].